8-K: Cardiff Oncology Presents Promising Onvansertib Data in mCRC

Cardiff Oncology announced positive Phase 2 data for onvansertib in combination with chemotherapy and bevacizumab for first-line RAS-mutated metastatic colorectal cancer, paving the way for a pivotal Phase 3 trial.

Summary

• Cardiff Oncology presented interim results from its Phase 2 CRDF-004 trial evaluating onvansertib in combination with standard-of-care (SoC) chemotherapy and bevacizumab for first-line RAS-mutated metastatic colorectal cancer (mCRC).
• The trial showed a 72% Objective Response Rate (ORR) with 30 mg onvansertib plus FOLFIRI/bevacizumab, a 30% improvement over the SoC (FOLFIRI/bevacizumab).
• Median Progression-Free Survival (PFS) was not reached in the onvansertib arm compared to 12.2 months in the SoC arm, with some patients remaining on treatment for over 18 months.
• The company has aligned with the FDA on a registrational trial design for a Phase 3 study, aiming for accelerated approval based on ORR and full approval based on PFS.
• The 30 mg dose of onvansertib combined with FOLFIRI/bevacizumab was selected for the registrational trial due to its efficacy and favorable safety profile.
• Onvansertib demonstrated synergy with FOLFIRI/bevacizumab, but not with FOLFOX/bevacizumab, due to mechanistic differences in DNA repair pathways and anti-angiogenic effects.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, with strong efficacy data and a clear regulatory path forward for onvansertib in a significant unmet medical need.

Positives

• Achieved a 72% Objective Response Rate (ORR) with 30 mg onvansertib + FOLFIRI/bevacizumab, a significant 30% improvement over the standard of care (SoC).
• Median Progression-Free Survival (PFS) was not reached in the 30 mg onvansertib + FOLFIRI/bevacizumab arm, compared to 12.2 months for the SoC (FOLFIRI/bevacizumab).
• Demonstrated deep and durable tumor shrinkage over time with the 30 mg onvansertib + FOLFIRI/bevacizumab combination.
• 9 out of 10 remaining patients in the onvansertib + FOLFIRI/bevacizumab arm were still on treatment as of the data cut-off.
• The combination of onvansertib with FOLFIRI/bevacizumab showed a favorable safety profile with no unexpected or overlapping toxicities.
• Successful End-of-Phase 2 meeting with the FDA, aligning on the registrational trial design for first-line RAS-mutated mCRC.
• The 30 mg dose of onvansertib plus FOLFIRI/bevacizumab was selected as the efficacious and safe dose for the registrational program.

Negatives

• Onvansertib did not show a consistent meaningful benefit when combined with FOLFOX/bevacizumab.
• The mechanistic rationale suggests onvansertib's synergy is primarily with FOLFIRI, not FOLFOX, due to differences in DNA repair pathways and anti-angiogenic effects.
• While median PFS was not reached in the onvansertib arm, the hazard ratio for PFS in some comparisons was not statistically significant, indicating a trend rather than a definitive outcome.
• The trial is ongoing, and the data presented are interim results as of March 18, 2026.

Risks

• Clinical trials involve lengthy and expensive processes with uncertain outcomes; earlier study results may not predict future trial results.
• Clinical trials may be suspended or discontinued due to unexpected side effects or safety risks.
• Results of preclinical studies or clinical trials could be unfavorable or delayed.
• The company has a need for additional financing.
• Uncertainty exists regarding the outcome of pending litigation against Nerviano Medical Sciences S.r.l.
• Risks related to business interruptions, including pandemics and cyber-attacks.
• Uncertainties of government or third-party payer reimbursement.
• Dependence on key personnel and limited experience in marketing and sales.

Future Outlook

The company is advancing to a pivotal Phase 3 trial (CRDF-005) in first-line RAS-mutated mCRC, designed to allow for accelerated approval based on ORR and full approval based on PFS. The FDA has been consulted on the trial design, and feedback from the EMA is pending. The proposed sample size for the Phase 3 trial is approximately 640 patients.

Management Comments

• Onvansertib is a highly selective PLK1 inhibitor with practice-changing potential in first-line RAS-mutated metastatic colorectal cancer.
• First-line RAS-mutated mCRC is an area of high unmet need and limited innovation, presenting an opportunity for market expansion.
• The Phase 3 trial is designed to allow for Accelerated Approval (ORR) and full approval (PFS).
• The 30 mg onvansertib + FOLFIRI/bev combination demonstrated a 72% ORR, a +30% improvement over SoC, and a median PFS that was not reached.
• The combination confirms earlier efficacy shown in a Phase 1b/2 trial in second-line KRAS-mut mCRC in bev-nave patients.
• Onvansertib targets all RAS-mutated mCRC, positioning it to address a large commercial opportunity with blockbuster potential.

Industry Context

StockSavvy.ai notes that the presented data for onvansertib in first-line RAS-mutated mCRC addresses a significant unmet medical need, as standard-of-care therapies have seen limited innovation over the past two decades. The positive results and clear path towards a registrational trial suggest Cardiff Oncology is well-positioned to compete in this large market segment.

Comparison to Industry Standards

• The 72% ORR achieved with onvansertib + FOLFIRI/bevacizumab significantly surpasses the ORR seen with historical first-line standard-of-care therapies for mCRC, which typically range from 45% to 65% in similar patient populations.
• The median PFS not being reached in the onvansertib arm contrasts with the median PFS of approximately 9.3 to 12.3 months observed in historical Phase 3 trials for chemotherapy and bevacizumab combinations (e.g., TRIBE trial).
• The mechanistic rationale for onvansertib's synergy with FOLFIRI, involving dual anti-angiogenic effects and potential inhibition of DNA repair pathways, provides a scientific basis for its improved efficacy compared to standard chemotherapy regimens alone.

Legal Proceedings

• There is uncertainty regarding the outcome of pending litigation against Nerviano Medical Sciences S.r.l. with respect to the license agreement.

Stakeholder Impact

• Shareholders: Potential for significant value creation if onvansertib receives regulatory approval and achieves commercial success.
• Patients: Offers a new, potentially more effective treatment option for a difficult-to-treat cancer with limited therapeutic advances.
• Healthcare Providers: Provides a new therapeutic strategy for managing first-line RAS-mutated mCRC.
• Competitors: May necessitate a re-evaluation of treatment strategies and R&D focus in the mCRC space.

Next Steps

• Initiate a pivotal Phase 3 trial (CRDF-005) for onvansertib in first-line RAS-mutated mCRC.
• Seek accelerated approval based on ORR and full approval based on PFS from regulatory authorities.
• Obtain feedback from the EMA on the proposed registrational trial design.

Key Dates

Recommendation

The strong efficacy data, particularly the significant improvement in ORR and the unreached median PFS, combined with a clean safety profile and a clear regulatory pathway for accelerated approval, present a compelling investment case. The addressing of a large unmet need in first-line RAS-mutated mCRC further supports a strong buy recommendation.

Keywords

onvansertib, metastatic colorectal cancer, mCRC, RAS-mutated, Cardiff Oncology, Phase 2 trial, Phase 3 trial, chemotherapy